How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2849-2855

  Bourget, P ^a   Amin, A ^a   Dupont, C ^b   Abely, M ^c   Desmazes Dufeu, N ^d   Dubus, J C ^e   Jouani, B L ^f   Merlette, C ^a   Nove Josserand R ^g   Pages, J ^g   Panzo, R ^b   Vidal, F ^a   Voge, F ^a   Hubert, D ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b université Paris Cité   (France)

^c AMERICAN MEMORIAL HOSPITAL   (France)

^d Hospital and University Centre   (France)

^e TIMONE HOSPITAL   (France)

^f Homecare Unit   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; PYRIDINE; ANTIINFECTIVE AGENT; PYRIDINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DRUG DEGRADATION; DRUG HALF LIFE; EXPOSURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INFUSION PUMP; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TEMPERATURE; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; METABOLISM;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CYSTIC FIBROSIS; HUMANS; INFUSIONS, INTRAVENOUS; KINETICS; PYRIDINES;

EID: 84898609020     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02637-13     Document Type: Article

References (30)

1. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA. 2011. A survey of the utilization of antipseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr. Pulmonol. 46:987-990. http://dx.doi.org/10.1002/ppul.21467.
2. Zhou M, Notari RE. 1995. Influence of pH, temperature, and buffers on the kinetics of ceftazidime degradation in aqueous solutions. J. Pharm. Sci. 84:534-538. http://dx.doi.org/10.1002/jps.2600840504.
3. Farina A, Porra R, Cotichini V, Doldo A. 1999. Stability of reconstituted solutions of ceftazidime for injections: an HPLC and CE approach. J. Pharm. Biomed. Anal. 20:521-530. http://dx.doi.org/10.1016/S0731-7085(99)00057-6.
4. Favetta P, Allombert C, Breysse C, Dufresne C, Guitton J, Bureau J. 2002. Fortum stability in different disposable infusion devices by pyridine assay. J. Pharm. Biomed. Anal. 27:873-879. http://dx.doi.org/10.1016/S0731-7085(01)00588- X.
5. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. 2002. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46:2327-2332. http://dx.doi.org/10.1128/AAC.46.8. 2327-2332.2002.
6. French National Institute of Research and Safety for the Prevention of Occupational Accidents and Diseases. 2011. INRS toxicological card of pyridine (FT 85). INRS, Paris, France.
7. National Toxicology Program. 2000. NTP technical report on the toxicology and carcinogenesis studies of pyridine (CAS no. 110-86-1) in F344/N rats, Wistar rats, and B6C3F1 mice (drinking water studies). Natl. Toxicol. Program Tech. Rep. Ser. 470:1-330.
8. Knegt-Junk C, Geursen-Reitsma L, van Joost T. 1993. Allergic contact dermatitis from pyridine in Karl Fischer reagent. Contact Dermatitis 28: 252. http://dx.doi.org/10.1111/j.1600-0536.1993.tb03421.x.
9. Sasseville D, Kwong P, Yu K. 1998. Narrow spectrum of crosssensitization with pyridine derivatives. Contact Dermatitis 38:212-214. http://dx.doi.org/10. 1111/j.1600-0536.1998.tb05711.x.
10. International Agency for Research on Cancer (IARC). 2005. Pyridine. IARC, Lyon, France. http://www.inchem.org/documents/iarc/vol77/77-16.html.
11. U.S. Pharmacopeia. 1995. United States Pharmacopeia/The National Formulary: USP 23-NF18. United States Pharmacopeia, Rockville, MD.
12. European Medicines Agency. 2010. ICH topic Q3C (R4). Impurities: guideline for residual solvent. European Medicines Agency, London, United Kingdom.
13. Plasse JC, Chabloz C, Terrier A, Bellon G. 2002. To the editor: is it safe to administer a continuous infusion of ceftazidime (Fortum) prepared for 24 hours in cystic fibrosis (CF) patients? Pediatr. Pulmonol. 33:232-233. http://dx.doi.org/10.1002/ppul.10051.
14. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, Grenet D, Sermet-Gaudelus I, Ramel S, Cracowski C, Sardet A, Wizla N, Deneuville E, Garraffo R. 2009. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob. Agents Chemother. 53:3650-3656. http://dx.doi.org/10.1128/AAC.00174-09.
15. Stendal TL, Klem W, Tonnesen HH, Kjonniksen I. 1998. Drug stability and pyridine generation in ceftazidime injection stored in an elastomeric infusion device. Am. J. Health Syst. Pharm. 55:683-685.
16. Hubert P, Nguyen-Huu JJ, Boulanger B, Chapuzet E, Chiap P, Cohen N, Compagnon PA, Dewe W, Feinberg M, Lallier M, Laurentie M, Mercier N, Muzard G, Nivet C, Valat L. 2004. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal-part I. J. Pharm. Biomed. Anal. 36:579-586. http://dx.doi.org/10.1016/j.jpba.2004.07.027.
17. Hubert P, Nguyen-Huu JJ, Boulanger B, Chapuzet E, Chiap P, Cohen N, Compagnon PA, Dewe W, Feinberg M, Lallier M, Laurentie M, Mercier N, Muzard G, Nivet C, Valat L, Rozet E. 2007. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal-part II. J. Pharm. Biomed. Anal. 45:70-81. http://dx.doi.org/10.1016/j.jpba.2007.06.013.
18. McKinnon PS, Davis SL. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur. J. Clin. Microbiol. Infect. Dis. 23:271-288. http://dx.doi.org/10.1007/s10096-004-1107-7.
19. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG. 2013. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins. Pediatr. Pulmonol. 48:107-122. http://dx.doi.org/10.1002/ppul.22669.
20. Craig WA. 2001. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. Respir. Med. 95(Suppl):S12-S19; discussion S26-S27.
21. Flume PA, Mogayzel PJ, Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. 2009. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 180: 802-808. http://dx.doi.org/ 10.1164/rccm.200812-1845PP.
22. Prescott WA, Jr, Gentile AE, Nagel JL, Pettit RS. 2011. Continuousinfusion antipseudomonal beta-lactam therapy in patients with cystic fibrosis. P T 36:723-763.
23. International Agency for Research on Cancer (IARC). 22 August 2000. Pyridine Summary and Evaluation. IARC Summaries and Evaluations. IPCS INCHEM. IARC, Lyon, France. http://www.inchem.org/documents/iarc/vol77/77-16.html.
24. Bui KQ, Ambrose PG, Nicolau DP, Lapin CD, Nightingale CH, Quintiliani R. 2001. Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients. Chemotherapy 47:153-156. http://dx.doi.org/10.1159/000063216.
25. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16:749-767. http://dx.doi.org/10.1034/j. 1399-3003.2000.16d30.x.
26. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. 2008. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J. Cyst. Fibros. 7:142-146. http://dx.doi.org/10.1016/j.jcf.2007.07.001.
27. Salh B, Bilton D, Dodd M, Abbot J, Webb K. 1992. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand. J. Infect. Dis. 24:215-218. http://dx.doi.org/10. 3109/00365549209052615.
28. Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R. 1989. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 8:858-865. http://dx.doi.org/10.1007/BF01963771.
29. Bosso JA, Bonapace CR, Flume PA, White RL. 1999. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 19:620-626. http://dx.doi.org/10.1592/phco.19.8.620.31525.
30. Rappaz I, Decosterd LA, Bille J, Pilet M, Belaz N, Roulet M. 2000. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-A-day bolus in cystic fibrosis children. Eur. J. Pediatr. 159:919-925. http://dx.doi.org/10.1007/PL00008370.